Swiss hearing aid maker Sonova resumes supplying Costco, source says
Oct 28 (Reuters) -Swiss hearing aid maker Sonova SOON.S is resuming supplies to Costco COST.O, a source with knowledge of the matter told Reuters on Monday.
Its shares rose as much as 7% to their highest in more than two years.
The product to be sold at Costco, a prescription hearing aid by the name of Sennheiser Sonite R which was specifically designed for the retailer, will initially be available in 107 locations in the United States, with a gradual expansion expected in the future, the source said.
The source added that it is typical for Costco to test sales of a product in a number of warehouses before a broader roll out.
The comments come after analysts at J.P. Morgan wrote in a note to clients that online reports on Friday had said Sonova was expected to replace Rexton as a supplier to Costco, after the Swiss company's previous agreement with the retailer was discontinued in 2022.
"I think there is the expectation already in terms of what the analysts are writing, that this will be, I mean, a gradual ramp-up," the source said.
J.P. Morgan analysts deemed the move "a positive surprise", noting Sonova and other hearing aid management teams had previously downplayed the possibility of a near-term return to Costco.
Sonova had previously been a supplier under Costco's own brand Kirkland Signature, the analysts noted.
"We do not believe re-entering Costco on the branded side will be worth as much as the previous KS contract, as Sonova will be competing with Demant and GN rather than being the sole supplier of KS," the analysts said.
The official launch of the Sennheiser product for Costco will come during Monday, the source said.
Costco was not immediately available for comment, while a spokesperson at Sennheiser Consumer division declined to comment.
In 2023, the company had reported a hit to its full-year 2022-23 profits from the loss of a big U.S. customer, whose name it did not disclose.
Sonova makes hearing aids under a number of brands, such as Phonak, Unitron, Hansaton and Sennheiser.
Reporting by Elizaveta Gladun and Linda Pasquini; Additional reporting by Neil J Kanatt; Editing by David Holmes
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
